284 related articles for article (PubMed ID: 31941838)
1. miR-543 regulates the epigenetic landscape of myelofibrosis by targeting TET1 and TET2.
Fuentes-Mattei E; Bayraktar R; Manshouri T; Silva AM; Ivan C; Gulei D; Fabris L; Soares do Amaral N; Mur P; Perez C; Torres-Claudio E; Dragomir MP; Badillo-Perez A; Knutsen E; Narayanan P; Golfman L; Shimizu M; Zhang X; Zhao W; Ho WT; Estecio MR; Bartholomeusz G; Tomuleasa C; Berindan-Neagoe I; Zweidler-McKay PA; Estrov Z; Zhao ZJ; Verstovsek S; Calin GA; Redis RS
JCI Insight; 2020 Jan; 5(1):. PubMed ID: 31941838
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
Chen YY; Huang CE; Lee KD; Chen CC
Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
[TBL] [Abstract][Full Text] [Related]
3. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
Talpaz M; Kiladjian JJ
Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
[TBL] [Abstract][Full Text] [Related]
4. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
5. Pharmacotherapy of Myelofibrosis.
Tremblay D; Marcellino B; Mascarenhas J
Drugs; 2017 Sep; 77(14):1549-1563. PubMed ID: 28791654
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for myelofibrosis.
Atallah E; Verstovsek S
Expert Opin Emerg Drugs; 2012 Dec; 17(4):555-70. PubMed ID: 23186315
[TBL] [Abstract][Full Text] [Related]
7. Practical management of patients with myelofibrosis receiving ruxolitinib.
Harrison C; Mesa R; Ross D; Mead A; Keohane C; Gotlib J; Verstovsek S
Expert Rev Hematol; 2013 Oct; 6(5):511-23. PubMed ID: 24083419
[TBL] [Abstract][Full Text] [Related]
8. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naive myelofibrosis.
Harrison CN; Gupta VK; Gerds AT; Rampal R; Verstovsek S; Talpaz M; Kiladjian JJ; Mesa R; Kuykendall AT; Vannucchi AM; Palandri F; Grosicki S; Devos T; Jourdan E; Wondergem MJ; Al-Ali HK; Buxhofer-Ausch V; Alvarez-Larrán A; Patriarca A; Kremyanskaya M; Mead AJ; Akhani S; Sheikine Y; Colak G; Mascarenhas J
Future Oncol; 2022 Sep; 18(27):2987-2997. PubMed ID: 35950489
[TBL] [Abstract][Full Text] [Related]
9. Current outlook on molecular pathogenesis and treatment of myeloproliferative neoplasms.
Tibes R; Bogenberger JM; Benson KL; Mesa RA
Mol Diagn Ther; 2012 Oct; 16(5):269-83. PubMed ID: 23023734
[TBL] [Abstract][Full Text] [Related]
10. Understanding Splenomegaly in Myelofibrosis: Association with Molecular Pathogenesis.
Song MK; Park BB; Uhm JE
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562644
[TBL] [Abstract][Full Text] [Related]
11. Management of myelofibrosis after ruxolitinib failure.
Harrison CN; Schaap N; Mesa RA
Ann Hematol; 2020 Jun; 99(6):1177-1191. PubMed ID: 32198525
[TBL] [Abstract][Full Text] [Related]
12. How I treat myelofibrosis.
Cervantes F
Blood; 2014 Oct; 124(17):2635-42. PubMed ID: 25232060
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
Kvasnicka HM; Thiele J; Bueso-Ramos CE; Sun W; Cortes J; Kantarjian HM; Verstovsek S
J Hematol Oncol; 2018 Mar; 11(1):42. PubMed ID: 29544547
[TBL] [Abstract][Full Text] [Related]
14. Ruxolitinib for myelofibrosis--an update of its clinical effects.
Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
[TBL] [Abstract][Full Text] [Related]
15. Momelotinib (JAK1/JAK2/ACVR1 inhibitor): mechanism of action, clinical trial reports, and therapeutic prospects beyond myelofibrosis.
Tefferi A; Pardanani A; Gangat N
Haematologica; 2023 Nov; 108(11):2919-2932. PubMed ID: 36861402
[TBL] [Abstract][Full Text] [Related]
16. Genetic ablation of Pim1 or pharmacologic inhibition with TP-3654 ameliorates myelofibrosis in murine models.
Dutta A; Nath D; Yang Y; Le BT; Rahman MF; Faughnan P; Wang Z; Stuver M; He R; Tan W; Hutchison RE; Foulks JM; Warner SL; Zang C; Mohi G
Leukemia; 2022 Mar; 36(3):746-759. PubMed ID: 34741118
[TBL] [Abstract][Full Text] [Related]
17. Definition and management of ruxolitinib treatment failure in myelofibrosis.
Pardanani A; Tefferi A
Blood Cancer J; 2014 Dec; 4(12):e268. PubMed ID: 25501025
[TBL] [Abstract][Full Text] [Related]
18. Clarifying the use of ruxolitinib in patients with myelofibrosis.
Kremyanskaya M; Atallah EL; Hoffman R; Mascarenhas JO
Oncology (Williston Park); 2013 Jul; 27(7):706-14. PubMed ID: 23977767
[TBL] [Abstract][Full Text] [Related]
19. Ruxolitinib is effective in patients with intermediate-1 risk myelofibrosis: a summary of recent evidence.
Harrison CN; Talpaz M; Mead AJ
Leuk Lymphoma; 2016 Oct; 57(10):2259-67. PubMed ID: 27463690
[TBL] [Abstract][Full Text] [Related]
20. Ten years after ruxolitinib approval for myelofibrosis: a review of clinical efficacy.
Pemmaraju N; Bose P; Rampal R; Gerds AT; Fleischman A; Verstovsek S
Leuk Lymphoma; 2023 Jun; 64(6):1063-1081. PubMed ID: 37081809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
